Comparative characteristics of the incidence of various endocrinopathies in cancer patients receiving treatment with immune checkpoint inhibitors

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

To date, there are at least 6 national and international guidelines for the management of endocrine complications associated with the use of immune checkpoint inhibitors (ICPIs). This article is a summary of the latest guidelines developed by a number of scientists on behalf of the European Society of Endocrinology (ESE). The article presents possible endocrine complications during therapy with anti-CTLA-4, anti-PD-1, anti-PD-L1 drugs and combination treatment with ipilimumab and nivolumab. Combination treatment with ICPIs with chemotherapy or targeted therapy is not discussed in the guidelines and article.

Толық мәтін

Рұқсат жабық

Авторлар туралы

I. Zhurtova

Department of Faculty Therapy, Medical Academy, Kabardino-Balkarian State University n.a. Kh.M. Berbekov

Хат алмасуға жауапты Автор.
Email: zhin07@mail.ru
ORCID iD: 0000-0003-0668-1073

Dr. Sci. (Med.), Professor at the Department of Faculty Therapy

Ресей, Nalchik

L. Aramisova

Department of Faculty Therapy, Medical Academy, Kabardino-Balkarian State University n.a. Kh.M. Berbekov

Email: zhin07@mail.ru
ORCID iD: 0000-0001-8105-4235
Ресей, Nalchik

H. Abdul Moati

Department of Faculty Therapy, Medical Academy, Kabardino-Balkarian State University n.a. Kh.M. Berbekov

Email: zhin07@mail.ru
ORCID iD: 0009-0009-4374-8442
Ресей, Nalchik

D. Arkhestova

Department of Faculty Therapy, Medical Academy, Kabardino-Balkarian State University n.a. Kh.M. Berbekov

Email: zhin07@mail.ru
ORCID iD: 0000-0002-5490-4166
Ресей, Nalchik

E. Khachmakhova

Department of Faculty Therapy, Medical Academy, Kabardino-Balkarian State University n.a. Kh.M. Berbekov

Email: zhin07@mail.ru
ORCID iD: 0009-0006-6537-3969
Ресей, Nalchik

Әдебиет тізімі

  1. Husebye E.S., et al. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical Practice Guideline. Eu. J Endocrinol. 2022;187(6):G1–21. Doi: 10.1530/ EJE-22-0689.
  2. Журтова И.Б., Эльгарова Л.В., Губачикова А.М. Иммунноопосредованные нежелательные эндокринные явления при лечении ингибиторами контрольных точек иммунного ответа: клинический опыт ниволумаб-индуцированного тиреоидита. Фарматека. 2022;7:90–4. хZhurtova I.B., Elgarova L.V., Gubachikova A.M. Immune-mediated endocrine adverse events during treatment with immune checkpoint inhibitors: a clinical case of nivolumab-induced thyroiditis Farmateka. 2022;7:90–4. (In Russ.)]. doi: 10.18565/pharmateca.2022.7.90-94.
  3. Martins F., Sofiya L., Sykiotis G.P., et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nature Reviews: Clin Oncol. 2019;16:563–80. doi: 10.1038/s41571-019-0218-0.
  4. Brahmer J.R., Lacchetti C., Schneider B.J., et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. JClin. Oncol. 2018;36:1714–68. Doi: 10.1200/ JCO.2017.77.6385.
  5. Castinetti F., Albarel F., Archambeaud F., et al. French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocrin Relat Cancer 2019;26:G1–18. doi: 10.1530/ERC-18- 0320.
  6. Paschou S.A., Stefanaki K., Psaltopoulou T., et al. How we treat endocrine complications of immune checkpoint inhibitors. ESMO Open. 2021;6:100011. doi: 10.1016/j.esmoop.2020.100011.
  7. Wright J.J., Powers A.C., Johnson D.B. Endocrine toxicities of immune checkpoint inhibitors. NatRev. Endocrinol. 2021;17:389–99. doi: 10.1038/s41574-021-00484-3.
  8. Di Dalmazi G., Ippolito S., Lupi I., Caturegli P. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. Exp Rev Endocrinol Metab. 2019;14:381–98. Doi: 10.1 080/17446651.2019.1701434.
  9. Bai X., Chen X., Wu X., et al. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study. J Endocrinol Invest. 2020;43:1473–83. doi: 10.1007/s40618-020-01226-4.
  10. Albarel F., Gaudy C., Castinetti F., et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015;172:195–204. Doi: 10.1530/ EJE-14-0845.
  11. Min L., Hodi F.S., Giobbie-Hurder A., et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res. 2015;21:749–55. doi: 10.1158/1078-0432.CCR-14-2353.
  12. Langlois F., Varlamov E.V., Fleseriu M. Hypophysitis, the growing spectrum of a rare pituitary disease. JClin. Endocrinol Metab. 2022;107:10–28. doi: 10.1210/clinem/dgab672.
  13. Tan M.H., Iyengar R., Mizokami-Stout K., et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin Diab Endocrinol. 2019;5:1. doi: 10.1186/s40842-018-0073-4.
  14. Faje A.T., Lawrence D., Flaherty K., et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124:3706–14. doi: 10.1002/cncr.31629.
  15. Stelmachowska-Banas M., Czajka-Oraniec I. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocrin Connect. 2020;9:R207–28. doi: 10.1530/EC-20-0342.
  16. Iyer P.C., Cabanillas M.E., Waguespack S.G., et al. Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid. 2018;28:1243–51. doi: 10.1089/thy.2018.0116.
  17. Stott D.J., Rodondi N., Kearney P.M., et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med. 2017;376:2534–44. https://doi. org/10.1056/NEJMoa1603825
  18. de Filette J., Andreescu C.E., Cools F., et al. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res. 2019;51:145–56. doi: 10.1055/a-0843-3366.
  19. Wright J.J., Salem J.E., Johnson D.B., et al. Increased reporting of immune checkpoint inhibitor-associated diabetes. Diab Care. 2018;41:e150–1. doi: 10.2337/dc18-1465.
  20. Goldenberg R.M., Berard L.D., Cheng A.Y.Y., et al. SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016;38:2654.e1–64. doi: 10.1016/j.clinthera.2016.11.002.
  21. Tran T.T.T., Pease A., Wood A..J., et al. Review of evidence for adult diabetic ketoacidosis management protocols. Front Endocrinol. 2017;8:106. Doi: /10.3389/fendo.2017.00106.
  22. Cardona Z., Sosman J.A., Chandra S., Huang W. Endocrine side effects of immune checkpoint inhibitors. Front Endocrinol (Lausanne). 2023;14:1157805. doi: 10.3389/fendo.2023.1157805.
  23. Trevisani V., Iughetti L., Lucaccioni L., Predieri B. Endocrine immune-related adverse effects of immune-checkpoint inhibitors. Exp Rev Endocrinol Metab. 2023;18(5):441–51. doi: 10.1080/17446651.2023.2256841.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2024

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>